Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2009Journal of Cardiovascular MedicineOpen Access

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do novel anticoagulants (FXa inhibitors and direct thrombin inhibitors) provide effective and safe alternatives to vitamin K antagonists for the prevention and treatment of thromboembolic diseases?

Population

Patients requiring prevention and treatment of thromboembolic diseases, in particular venous thromboembolism

Comparison

Novel anticoagulants, specifically selective FXa… vs Conventional vitamin K antagonists

Design

Review

Authors

JSJan SteffelTLThomas F. Lüscher

Discussion

Loading...

Member takes

Overview

May support NOACs as VKA alternatives without monitoring; leaves open optimal agent selection in subgroups.

Structured PICO

Do novel anticoagulants (FXa inhibitors and direct thrombin inhibitors) provide effective and safe alternatives to vitamin K antagonists for the prevention and treatment of thromboembolic diseases?

P
Population
Patients requiring prevention and treatment of thromboembolic diseases, in particular venous thromboembolism
I
Intervention
Novel anticoagulants, specifically selective FXa inhibitors (fondaparinux, rivaroxaban, apixaban) and direct thrombin inhibitors (lepirudin, bivalirudin, dabigatran etexilate)
C
Comparator
Conventional vitamin K antagonists
O
Outcome
Efficacy and safety in the prevention and treatment of venous thromboembolism

Novel anticoagulants, including FXa and direct thrombin inhibitors, offer effective and safe alternatives to vitamin K antagonists for thromboembolic disease management without the need for regular monitoring.

Cite This Study

Steffel et al. (2009) studied this question.

synapsesocial.com/papers/6a763feb8cd3ec459187ff3bhttps://doi.org/10.2459/jcm.0b013e32832edac0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>2002 · 736 citations
  2. 2Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty2008 · 1,302 citations
  3. 3Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty2008 · 1,439 citations
  4. 4A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study2008 · 347 citations
  5. 5Secondary Prophylaxis with Warfarin for Venous Thromboembolism2003 · 173 citations